Clinical relevance of protein-truncating variants of germline DNA repair genes in prostate cancer.
DNA repair gene
Germline mutation
Prostate cancer
Protein-truncating variant
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
17
09
2023
accepted:
08
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
Interpreting genetic variants remains a challenge in prostate cancer (PCa). Although many annotation tools are available for prioritizing causal variants, the clinical relevance of these variants is rarely studied. We collected a cohort study that included 274 PCa patients from June 2017 to December 2020 and sequenced 19 DNA damage repair (DDR) genes in these patients and explored the clinical consequence of these different approaches. We also examined all-cause and PCa-specific survival in DDR gene mutation carriers compared to non-carriers after androgen receptor (AR)-directed therapy. We identified 13 variants from 19 DDR genes in a total of 14 (5.1%) patients who had at least one presumed pathogenic mutation using different annotation methods. Four variants were annotated as pathogenic, 11 variants were predicted as protein-truncating variants (PTVs), four variants received proxy-deleterious (Combined Annotation-Dependent Depletion scores of > 30), and only one variant was identified as a pathogenic variant or as having a functional effect by all three methods. PCa patients with PTVs were significantly associated with early onset, high cancer stage, and a worse response to AR-directed treatment. However, patients carrying a proxy-deleterious variant were only associated with a higher T (tumor) stage and N (node) stage than those without such a variant, but not associated with other clinical characteristics. In patients treated with AR-directed therapy, patients with a PTV showed an increased risk of all-cause death (adjusted hazard ratio (aHR) = 3.51, 95% confidence interval (CI): 1.06 ~ 11.56) and PCa-specific death (aHR = 4.49, 95% CI: 1.87 ~ 10.77) compared to non-PTV carriers after adjustment. We were unable to examine gene-specific risks due to the small number of patients. PTVs may assist in guiding treatment and early screening in PCa, while population-specific data for pathogenic variants are still being amassed.
Sections du résumé
BACKGROUND
BACKGROUND
Interpreting genetic variants remains a challenge in prostate cancer (PCa). Although many annotation tools are available for prioritizing causal variants, the clinical relevance of these variants is rarely studied.
METHODS
METHODS
We collected a cohort study that included 274 PCa patients from June 2017 to December 2020 and sequenced 19 DNA damage repair (DDR) genes in these patients and explored the clinical consequence of these different approaches. We also examined all-cause and PCa-specific survival in DDR gene mutation carriers compared to non-carriers after androgen receptor (AR)-directed therapy.
RESULTS
RESULTS
We identified 13 variants from 19 DDR genes in a total of 14 (5.1%) patients who had at least one presumed pathogenic mutation using different annotation methods. Four variants were annotated as pathogenic, 11 variants were predicted as protein-truncating variants (PTVs), four variants received proxy-deleterious (Combined Annotation-Dependent Depletion scores of > 30), and only one variant was identified as a pathogenic variant or as having a functional effect by all three methods. PCa patients with PTVs were significantly associated with early onset, high cancer stage, and a worse response to AR-directed treatment. However, patients carrying a proxy-deleterious variant were only associated with a higher T (tumor) stage and N (node) stage than those without such a variant, but not associated with other clinical characteristics. In patients treated with AR-directed therapy, patients with a PTV showed an increased risk of all-cause death (adjusted hazard ratio (aHR) = 3.51, 95% confidence interval (CI): 1.06 ~ 11.56) and PCa-specific death (aHR = 4.49, 95% CI: 1.87 ~ 10.77) compared to non-PTV carriers after adjustment. We were unable to examine gene-specific risks due to the small number of patients.
CONCLUSIONS
CONCLUSIONS
PTVs may assist in guiding treatment and early screening in PCa, while population-specific data for pathogenic variants are still being amassed.
Identifiants
pubmed: 39455978
doi: 10.1186/s12885-024-13045-4
pii: 10.1186/s12885-024-13045-4
doi:
Substances chimiques
Receptors, Androgen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1319Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 108-2314-B-038-091
Organisme : Janssen Pharmaceuticals
ID : JJ-64091742PCR4001
Organisme : Janssen Pharmaceuticals
ID : JJ-64091742PCR4001
Informations de copyright
© 2024. The Author(s).
Références
Beebe-Dimmer JL, Drake EA, Dunn RL, Bock CH, Montie JE, Cooney KA. Association between family history of prostate and breast cancer among African-American men with prostate cancer. Urology. 2006;68(5):1072–6.
Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG, Swanson GM, Silverman DT, Brown LM, Hoover RN, et al. Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer. 1995;60(3):361–4.
doi: 10.1002/ijc.2910600315
pubmed: 7829245
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R et al. Inherited DNA-Repair gene mutations in men with metastatic prostate Cancer. 2016, 375(5):443–53.
Abdi B, Basset N, Perrot E, Benderra MA, Khalil A, Oudard S, Blanchet P, Brureau L, Coulet F, Cussenot O, et al. DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries. Prostate. 2022;82(12):1196–201.
doi: 10.1002/pros.24374
pubmed: 35652560
Darst BF, Dadaev T, Saunders E, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Gapstur SM, et al. Germline sequencing DNA repair genes in 5545 men with aggressive and nonaggressive prostate Cancer. JNCI: J Natl Cancer Inst. 2020;113(5):616–25.
doi: 10.1093/jnci/djaa132
pmcid: 8599772
Momozawa Y, Iwasaki Y, Hirata M, Liu X, Kamatani Y, Takahashi A, Sugano K, Yoshida T, Murakami Y, Matsuda K, et al. Germline pathogenic variants in 7636 Japanese patients with prostate Cancer and 12 366 controls. JNCI: J Natl Cancer Inst. 2019;112(4):369–76.
doi: 10.1093/jnci/djz124
pmcid: 7156928
Wei Y, Wu J, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y, Ye D. Germline DNA repair Gene Mutation Landscape in Chinese prostate Cancer patients. Eur Urol. 2019;76(3):280–3.
doi: 10.1016/j.eururo.2019.06.004
pubmed: 31248605
Wu J, Wei Y, Pan J, Jin S, Gu W, Gan H, Zhu Y, Ye DW. Prevalence of comprehensive DNA damage repair gene germline mutations in Chinese prostate cancer patients. Int J Cancer. 2021;148(3):673–81.
doi: 10.1002/ijc.33324
pubmed: 33006389
So M-K, Ahn HK, Huh J, Kim KH. Germline pathogenic variants in unselected Korean men with prostate cancer. Investig Clin Urol. 2022;63(3):294–300.
doi: 10.4111/icu.20220044
pubmed: 35534218
pmcid: 9091831
Castro E, Romero-Laorden N, Pozo Ad, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, et al. PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate Cancer. J Clin Oncol. 2019;37(6):490–503.
doi: 10.1200/JCO.18.00358
pubmed: 30625039
Nugent A, Conatser KR, Turner LL, Nugent JT, Sarino EMB, Ricks-Santi LJ. Reporting of race in genome and exome sequencing studies of cancer: a scoping review of the literature. Genet Sci. 2019;21(12):2676–80.
Caswell-Jin JL, Gupta T, Hall E, Petrovchich IM, Mills MA, Kingham KE, Koff R, Chun NM, Levonian P, Lebensohn AP, et al. Racial/ethnic differences in multiple-gene sequencing results for hereditary cancer risk. Genet Sci. 2018;20(2):234–9.
Yadav S, LaDuca H, Polley EC, Hu C, Niguidula N, Shimelis H, Lilyquist J, Na J, Lee KY, Gutierrez S, et al. Racial and ethnic differences in Multigene Hereditary Cancer Panel Test results for women with breast Cancer. J Natl Cancer Inst. 2021;113(10):1429–33.
doi: 10.1093/jnci/djaa167
pubmed: 33146377
van der Velde KJ, de Boer EN, van Diemen CC, Sikkema-Raddatz B, Abbott KM, Knopperts A, Franke L, Sijmons RH, de Koning TJ, Wijmenga C, et al. GAVIN: gene-aware variant INterpretation for medical sequencing. Genome Biol. 2017;18(1):6.
doi: 10.1186/s13059-016-1141-7
pubmed: 28093075
pmcid: 5240400
Itan Y, Shang L, Boisson B, Ciancanelli MJ, Markle JG, Martinez-Barricarte R, Scott E, Shah I, Stenson PD, Gleeson J, et al. The mutation significance cutoff: gene-level thresholds for variant predictions. Nat Methods. 2016;13(2):109–10.
doi: 10.1038/nmeth.3739
pubmed: 26820543
pmcid: 4980758
American Joint Committee on Cancer. Manual for staging of Cancer, Fifth Edition, Fifth edn. Philadelphia: JB Lippincott; 1997.
Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012;10(9):1081–7.
doi: 10.6004/jnccn.2012.0114
pubmed: 22956807
Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015;10(10):1556–66.
doi: 10.1038/nprot.2015.105
pubmed: 26379229
pmcid: 4718734
Landrum MJ, Chitipiralla S, Brown GR, Chen C, Gu B, Hart J, Hoffman D, Jang W, Kaur K, Liu C, et al. ClinVar: improvements to accessing data. Nucleic Acids Res. 2020;48(D1):D835–44.
doi: 10.1093/nar/gkz972
pubmed: 31777943
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–11.
doi: 10.1093/nar/29.1.308
pubmed: 11125122
pmcid: 29783
Chen C-H, Yang J-H, Chiang CWK, Hsiung C-N, Wu P-E, Chang L-C, Chu H-W, Chang J, Song IW, Yang S-L, et al. Population structure of Han Chinese in the modern Taiwanese population based on 10,000 participants in the Taiwan Biobank project. Hum Mol Genet. 2016;25(24):5321–31.
pubmed: 27798100
pmcid: 6078601
Richards CS, Bale S, Bellissimo DB, Das S, Grody WW, Hegde MR, Lyon E, Ward BE. ACMG recommendations for standards for interpretation and reporting of sequence variations: revisions 2007. Genet Med. 2008;10(4):294–300.
doi: 10.1097/GIM.0b013e31816b5cae
pubmed: 18414213
Li Q, Wang K. InterVar: clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Hum Genet. 2017;100(2):267–80.
doi: 10.1016/j.ajhg.2017.01.004
pubmed: 28132688
pmcid: 5294755
Morales J, Pujar S, Loveland JE, Astashyn A, Bennett R, Berry A, Cox E, Davidson C, Ermolaeva O, Farrell CM, et al. A joint NCBI and EMBL-EBI transcript set for clinical genomics and research. Nature. 2022;604(7905):310–5.
doi: 10.1038/s41586-022-04558-8
pubmed: 35388217
pmcid: 9007741
Rentzsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1):D886–94.
doi: 10.1093/nar/gky1016
pubmed: 30371827
Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496–509.
doi: 10.1080/01621459.1999.10474144
Na R, Zheng SL, Han M, Yu H, Jiang D, Shah S, Ewing CM, Zhang L, Novakovic K, Petkewicz J, et al. Germline mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and indolent prostate Cancer and are Associated with early age at death. Eur Urol. 2017;71(5):740–7.
doi: 10.1016/j.eururo.2016.11.033
pubmed: 27989354
Shibata A, Jeggo PA. ATM’s Role in the Repair of DNA Double-Strand Breaks. Genes (Basel) 2021, 12(9).
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, et al. Olaparib for metastatic castration-resistant prostate Cancer. N Engl J Med. 2020;382(22):2091–102.
doi: 10.1056/NEJMoa1911440
pubmed: 32343890
Weigelt B, Bi R, Kumar R, Blecua P, M DL, G FC, Pareja F, J PA, Investigators k, C FJ, et al. The Landscape of somatic genetic alterations in breast cancers from ATM Germline Mutation Carriers. JNCI: J Natl Cancer Inst. 2018;110(9):1030–4.
Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, Schweizer MT, Antonarakis ES. Differential Response to Olaparib Treatment among men with metastatic castration-resistant prostate Cancer harboring BRCA1 or BRCA2 Versus ATM mutations. Eur Urol. 2019;76(4):452–8.
doi: 10.1016/j.eururo.2019.02.002
pubmed: 30797618
pmcid: 6703974
Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppala IL, So A, Lo G, et al. Treatment outcomes and tumor loss of Heterozygosity in germline DNA repair-deficient prostate Cancer. Eur Urol. 2017;72(1):34–42.
doi: 10.1016/j.eururo.2017.02.023
pubmed: 28259476
Antonarakis ES, Lu C, Luber B, Liang C, Wang H, Chen Y, Silberstein JL, Piana D, Lai Z, Chen Y, et al. Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate Cancer receiving first-line Abiraterone and Enzalutamide. Eur Urol. 2018;74(2):218–25.
doi: 10.1016/j.eururo.2018.01.035
pubmed: 29439820
pmcid: 6045965
Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate Cancer: results from NCI 9012. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(10):991–9.
doi: 10.1200/JCO.2017.75.7310
Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, et al. Clinical outcome of prostate Cancer patients with germline DNA repair mutations: retrospective analysis from an International Study. Eur Urol. 2018;73(5):687–93.
doi: 10.1016/j.eururo.2018.01.010
pubmed: 29429804
pmcid: 6745088
Marcos C, Laorden R, Rodriguez JMP, Pozo Ad, Sáez MI, Colmenero AM, Puente J, Silla-Castro JC, Mejorada RL, Garcia-Carbonero I, et al. PROREPAIR-B: a prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC). Ann Oncol. 2017;28(suppl5):mdx440025.
NCCN Guidelines Version 1. 2023: Genetic/Familial High- Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2022). [ https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf ]
NCCN Guidelines Version 1. 2022: Prostate Cancer Early Detection [ https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf ]